Spebrutinib

DB11764InvestigationalSmall molecule

Spebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell.

Chemical structure of Spebrutinib
Formula / weight
C22H22FN5O3 · 423.448 g/mol (avg)
Also known as
3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE · BTK inhibitor CC-292 · N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
Code names
AVL-292 · CC-292

Resolves to

Compound
UNIIDRU6NG543JCAS1202757-89-8ChEMBLCHEMBL3301625PubChem59174488
Structure
InChIKeyKXBDTLQSDKGAEB-UHFFFAOYSA-NSMILESCOCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC=CC(NC(=O)C=C)=C3)=N2)C=C1
Targets
Q06187BTK

What you can answer from here — as of July 18, 2023

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Spebrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In